ArticleMolecules (Basel, Switzerland)2018
Effects of Mogrosides on High-Fat-Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Mogroside-Rich Monk Fruit Extract Improves Glycemic Control Without Promoting Additional Weight Gain Compared With Sucralose and Sucrose in High-Fat Diet-Induced Obese Mice.Food science & nutrition · 2026Article
- Cucurbitane Glycosides fromMolecules (Basel, Switzerland) · 2025Article
- Effects of Mogroside V on Quality and Antioxidant Activity of Boar Frozen-Thawed Sperm.Antioxidants (Basel, Switzerland) · 2025Article
- Early-life gut mycobiome core species modulate metabolic health in mice.Nature communications · 2025Article
- Mogrosides Protect Against Diabetic Kidney Injury via Inhibiting Macrophage Activation in a Mouse Model.Journal of diabetes research · 2025Article
- Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease.Lipids in health and disease · 2024Article
- Post-Ripening and Key Glycosyltransferase Catalysis to Promote Sweet Mogrosides Accumulation ofMolecules (Basel, Switzerland) · 2023Article
- Effects ofJournal of toxicologic pathology · 2023Article
- Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy.Molecules (Basel, Switzerland) · 2022Review
- A Review of the Phytochemistry and Pharmacology of the Fruit ofMolecules (Basel, Switzerland) · 2022Review
- Mogroside-Rich Extract FromFrontiers in nutrition · 2022Article
- Hepatoprotective effect of botanical drug formula on high-fat diet-induced non-alcoholic fatty liver disease by inhibiting lipogenesis and promoting anti-oxidation.Frontiers in pharmacology · 2022Article
- Mogroside IIe Ameliorates Cardiomyopathy by Suppressing Cardiomyocyte Apoptosis in a Type 2 Diabetic Model.Frontiers in pharmacology · 2021Article
- Mogroside V Alleviates Oocyte Meiotic Defects and Quality Deterioration in Benzo(a)pyrene-Exposed Mice.Frontiers in pharmacology · 2021Article
- Mogroside V Protects Porcine Oocytes From Lipopolysaccharide-Induced Meiotic Defects.Frontiers in cell and developmental biology · 2021Article
- Relationship among porcine lncRNA TCONS_00010987, miR-323, and leptin receptor based on dual luciferase reporter gene assays and expression patterns.Asian-Australasian journal of animal sciences · 2020Article
- Mogroside IIIE Alleviates High Glucose-Induced Inflammation, Oxidative Stress and Apoptosis of Podocytes by the Activation of AMPK/SIRT1 Signaling Pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Mogroside V protects porcine oocytes fromAging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and nonalcoholic fatty liver disease (NAFLD) are highly prevalent and cause numerous metabolic diseases. However, drugs for the prevention and treatment of obesity and NAFLD remain unavailable. In this study, we investigated the effects of mogrosides (luo han guo, LH) in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.